Morgan Stanley Private Equity Asia to de-list Singapore drug maker | AltAssets Private Equity News

Subscribe today

Advanced
Search

Morgan Stanley Private Equity Asia to de-list Singapore drug maker

26 Aug 2009

Morgan Stanley Private Equity Asia has made an offer to de-list Sihuan Pharmaceutical through MSPE Asia’s investment firm China Pharma, according to reports.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.